SECsense Logo

Opthea Limited's Form 6-K: Clinical Trial Milestone Report Filed with SEC

$OPT
Form 6-K
Filed on: 2025-02-18
Source
Opthea Limited's Form 6-K: Clinical Trial Milestone Report Filed with SEC

Here are the key insights extracted from the provided section of the financial report (Form 6-K) for Opthea Limited:

  1. Document Type and Filing:
  • The document is a Form 6-K filed with the U.S. Securities and Exchange Commission (SEC) as a report of a foreign issuer pursuant to specific rules under the Securities Exchange Act of 1934.
  1. Filing Date:
  • The report is dated February 18, 2025.
  1. Company Information:
  • The registrant is Opthea Limited, which is based in South Yarra, Victoria, Australia. The company's address is Level 4, 650 Chapel Street, South Yarra, Victoria, 3141.
  1. Commission File Number:
  • The filing is associated with Commission File No. 001-39621.
  1. Exhibit Index:
  • The report includes an exhibit (99.1) titled "Opthea Completes COAST Final Week 52 Patient Visit," indicating a completion of a significant phase in clinical trials or studies.
  1. Signatory Information:
  • The report is signed by Frederic Guerard, who is the Chief Executive Officer (CEO) of Opthea Limited. The signature implies formal acknowledgment of the contents of the report.
  1. Regulatory Compliance:
  • The report fulfills the requirements of the Securities Exchange Act, indicating that the company is compliant with its obligations to provide relevant information to the SEC.

These points provide a concise overview of the essential details contained in the filing, highlighting the company's regulatory compliance, significant clinical milestones, and executive leadership involvement in the filing process.